Table 1. Patient characteristics:... | American Society of Hematology

Table 1.

Patient characteristics: analysis A

	1989-2008 (n = 785)		2009-2018 (n = 642)
	n	%	n	%
Male sex	494	63	398	62
Age at diagnosis, y
Median	50		54
Range	18-64		18-64
Subtype of T-cell NHL
ALCL	287	37	219	34
PTCL NOS	381	48	246	38
AITL*	117	15	177	27
First-line therapy
Chemotherapy and ASCT	39	5	201	31
Chemotherapy only	591	75	367	57
Radiotherapy	9	1	1	0
Chemotherapy and radiotherapy	61	8	15	3
Other or no therapy	85	11	58	9
Follow-up, mo
Median	22.4		32.0
Range	0.03-382.6		0.03-143.4

	1989-2008 (n = 785)		2009-2018 (n = 642)
	n	%	n	%
Male sex	494	63	398	62
Age at diagnosis, y
Median	50		54
Range	18-64		18-64
Subtype of T-cell NHL
ALCL	287	37	219	34
PTCL NOS	381	48	246	38
AITL*	117	15	177	27
First-line therapy
Chemotherapy and ASCT	39	5	201	31
Chemotherapy only	591	75	367	57
Radiotherapy	9	1	1	0
Chemotherapy and radiotherapy	61	8	15	3
Other or no therapy	85	11	58	9
Follow-up, mo
Median	22.4		32.0
Range	0.03-382.6		0.03-143.4

Patients aged <65 y with stage II to IV disease at diagnosis with ALTL, AITL, and PTCL NOS in The Netherlands.

Including T-cell NHL, follicular helper T cells.